A VIEWPOINT ON DRUGS THAT PROLONG THE QT(C) INTERVAL

Insufficient evidence exists to suggest that prolongation of the QT interval corrected for heart rate (QT(c)) is necessarily beneficial. In all but life-threatening situations, QT(c) prolongation resulting from pharmacologic agents must be considered a risk. Because dose-response relations for torsades de pointes cannot be established and because prolongation of the QT(c) interval is thought to precede the development of torsades, it is reasonable to assume that the QT(c) prolongation itself constitutes the marker of risk. An assessment of the relation between the dose of a given drug and its effect on the QT(c) interval will aid in making the judgement that the potential benefit outweighs the risk. Ideally, a drug should demonstrate as wide a safety margin as possible, as reflected in a large separation between the ED50 value associated with therapeutic benefit and that associated with QT(c) prolongation.